Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma

• Egile Nagusiak: Zibi Marchocki (Egilea), Alicia Tone (Egilea), Carl Virtanen (Egilea), Richard de Borja (Egilea), Blaise Clarke (Egilea), Theodore Brown (Egilea), Taymaa May (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2022-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Patients treated with neoadjuvant chemotherapy (NACT) for advanced high-grade serous ovarian carcinoma (HGSC) have a higher rate and shorter time to platinum-resistant recurrence compared to patients treated with primary cytoreductive surgery (PCS) and adjuvant chemotherapy. The...